



## Clinical trial results:

**A Phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily**

**EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patients with chronic HeArt FaiLure with reduced Ejection Fraction (HFrEF) (EMPERIAL – reduced)**

### Summary

EudraCT number	2017-004073-14
Trial protocol	ES GR PT PL SE NO IT
Global end of trial date	07 October 2019

### Results information

Result version number	v2 (current)
This version publication date	01 December 2021
First version publication date	15 October 2020
Version creation reason	

### Trial information

#### Trial identification

Sponsor protocol code	1245-0168
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03448419
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Boehringer Ingelheim
Sponsor organisation address	Binger Straße 173, Ingelheim am Rhein, Germany, 55216
Public contact	Boehringer Ingelheim, Call Centre, Boehringer Ingelheim, 001 8002430127, <a href="mailto:clintrriage.rdg@boehringer-ingelheim.com">clintrriage.rdg@boehringer-ingelheim.com</a>
Scientific contact	Boehringer Ingelheim, Call Centre, Boehringer Ingelheim, 001 8002430127, <a href="mailto:clintrriage.rdg@boehringer-ingelheim.com">clintrriage.rdg@boehringer-ingelheim.com</a>

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 November 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 September 2019
Global end of trial reached?	Yes
Global end of trial date	07 October 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the trial was to evaluate the effect of empagliflozin 10 mg vs. placebo on exercise ability using the 6-minute walk test (6MWT) in patients with chronic heart failure (CHF) with reduced left ventricular ejection fraction (LVEF  $\leq 40\%$ ). Secondary objectives were to assess patient-reported Outcomes (PRO).

Protection of trial subjects:

Only subjects that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all subjects was adhered to throughout the trial conduct. An independent DMC was formed to monitor patients' safety throughout the conduct of the trial at regular meetings. An independent external CEC adjudicated selected hepatic events and ketoacidosis while blinded to the patient's treatment allocation.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 March 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 12
Country: Number of subjects enrolled	Canada: 17
Country: Number of subjects enrolled	Germany: 63
Country: Number of subjects enrolled	Spain: 52
Country: Number of subjects enrolled	Greece: 37
Country: Number of subjects enrolled	Italy: 27
Country: Number of subjects enrolled	Norway: 20
Country: Number of subjects enrolled	Poland: 101
Country: Number of subjects enrolled	Portugal: 44
Country: Number of subjects enrolled	Sweden: 17
Country: Number of subjects enrolled	United States: 317
Worldwide total number of subjects	707
EEA total number of subjects	361

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	258
From 65 to 84 years	424
85 years and over	25

## Subject disposition

### Recruitment

Recruitment details:

Randomised, double-blind, placebo-controlled, parallel-group trial in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF) to evaluate the effect of Empagliflozin versus Placebo on exercise and heart failure symptoms.

### Pre-assignment

Screening details:

Only subjects that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all subjects was adhered to throughout the trial conduct.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

Patients, investigators, and everyone involved in trial conduct or analysis or with any other interest in this double-blind trial remained blinded with regard to the randomised treatment assignments until after database lock. The randomisation code was kept secret by Clinical Trial Support up to database lock.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

1 film-coated tablet of placebo matching empagliflozin was administered orally once daily for 12 weeks in subjects with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction (LVEF $\leq$ 40%).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

1 film-coated tablet of placebo matching empagliflozin was administered orally once daily for 12 weeks in subjects with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction (LVEF $\leq$ 40%).

<b>Arm title</b>	10 mg Empagliflozin
------------------	---------------------

Arm description:

1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily for 12 weeks in subjects with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction (LVEF $\leq$ 40%).

Arm type	Experimental
Investigational medicinal product name	Empagliflozin
Investigational medicinal product code	
Other name	Jardiance®
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

1 film-coated tablet of 10 milligram (mg) of Empagliflozin was administered orally once daily for 12 weeks in subjects with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction

(LVEF $\leq$ 40%).

<b>Number of subjects in period 1<sup>[1]</sup></b>	Placebo	10 mg Empagliflozin
Started	156	156
Treated	156	155
Completed	143	140
Not completed	13	16
Adverse event, serious fatal	3	1
Consent withdrawn by subject	3	1
Withdrawn by Sponsor	-	1
Adverse event, non-fatal	7	8
Lost to follow-up	-	2
Patient did not attend all visits	-	2
Not treated	-	1

---

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 707 subjects were enrolled worldwide and thereof 312 subjects were included in the trial.

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description:	
1 film-coated tablet of placebo matching empagliflozin was administered orally once daily for 12 weeks in subjects with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction (LVEF≤40%).	
Reporting group title	10 mg Empagliflozin
Reporting group description:	
1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily for 12 weeks in subjects with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction (LVEF≤40%).	

Reporting group values	Placebo	10 mg Empagliflozin	Total
Number of subjects	156	156	312
Age categorical			
Randomised Set: All subjects that were randomised, regardless of whether treated or not.			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	48	47	95
From 65-84 years	97	106	203
85 years and over	11	3	14
Age Continuous			
Randomised Set: All subjects that were randomised, regardless of whether treated or not.			
Units: years			
arithmetic mean	69.3	68.7	
standard deviation	± 10.6	± 9.9	-
Sex: Female, Male			
Randomised Set: All subjects that were randomised, regardless of whether treated or not.			
Units: Subjects			
Female	45	35	80
Male	111	121	232
Race (NIH/OMB)			
Randomised Set: All subjects that were randomised, regardless of whether treated or not.			
Units: Subjects			
American Indian or Alaska Native	1	1	2
Asian	2	1	3
Native Hawaiian or Other Pacific Islander	1	0	1
Black or African American	18	24	42
White	133	130	263
More than one race	0	0	0
Unknown or Not Reported	1	0	1
Ethnicity (NIH/OMB)			

Randomised Set: All subjects that were randomised, regardless of whether treated or not.			
Units: Subjects			
Hispanic or Latino	23	20	43
Not Hispanic or Latino	132	136	268
Unknown or Not Reported	1	0	1
Exercise capacity as measured by the 6-Minutes-Walking-Test (6MWT) distance at baseline			
6 Minute Walking test measures the distance walked in 6 minutes in standardised conditions at baseline. Randomised Set: All subjects that were randomised, regardless of whether treated or not.			
Units: Meter			
median	309.0	306.0	
inter-quartile range (Q1-Q3)	248.5 to 332.0	260.0 to 333.5	-

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description:	
1 film-coated tablet of placebo matching empagliflozin was administered orally once daily for 12 weeks in subjects with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction (LVEF≤40%).	
Reporting group title	10 mg Empagliflozin
Reporting group description:	
1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily for 12 weeks in subjects with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction (LVEF≤40%).	

### Primary: Change from baseline to week 12 in exercise capacity as measured by the 6-Minutes-Walking-Test (6MWT) distance

End point title	Change from baseline to week 12 in exercise capacity as measured by the 6-Minutes-Walking-Test (6MWT) distance
End point description:	
Change from baseline to week 12 in exercise capacity as measured by the distance walked in 6 minutes in standardised conditions. If repeated 6MWT measurements were available for the same day, the longest distance was used for analysis. Change from baseline was defined as the distance walked in 6 minutes at week 12 minus the baseline value. Baseline value was defined as the last available measurement before start of treatment with randomised study medication. If a subject was present at the visit at week 12 but did not perform the 6MWT, the subject was evaluated as having walked a distance of 0 meter. If no value was available for week 12, an imputed value was used. Patients with missing week 12 data who had no clinical event were ranked below any patient with non-missing data, but above the patients who had clinical events. Patients who died before week 12 were ranked below the patients in all categories above. Randomised Set (RS).	
End point type	Primary
End point timeframe:	
At baseline and at week 12	

End point values	Placebo	10 mg Empagliflozin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	156 <sup>[1]</sup>	156 <sup>[2]</sup>		
Units: Meter (m)				
median (inter-quartile range (Q1-Q3))	18.0 (-11.5 to 54.0)	13.5 (-8.0 to 42.0)		

Notes:

[1] - RS

[2] - RS

### Statistical analyses

Statistical analysis title	Superiority of Empagliflozin vs. Placebo
Statistical analysis description:	
H0: There is no difference between the effect of placebo and the effect of empagliflozin.	
Comparison groups	Placebo v 10 mg Empagliflozin



Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.4236
Method	Wilcoxon rank test, normal approximation
Parameter estimate	Median difference (HL-estimate)
Point estimate	-4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16
upper limit	6

## Secondary: Change from baseline to week 12 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS)

End point title	Change from baseline to week 12 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS)
-----------------	--

### End point description:

Change from baseline in KCCQ-TSS was defined as the endpoint value at week 12 minus the last available measurement before start of treatment with randomised study medication. The KCCQ is 23 item self-administered questionnaire and comprises 7 domains: physical limitation, symptom frequency, symptom burden, symptom stability, social limitation, self-efficacy and quality of life. Additionally 3 summary scores exist: TSS, clinical summary score, and overall summary score. The scores of the KCCQ domains and summary scores range from 0 to 100, with higher score indicating better outcome. If no questionnaire was available at week 12, an imputed value was used. Patients with missing week 12 data who had no clinical event were ranked below any patient with non-missing data, but above the patients who had clinical events. Patients who died before week 12 were ranked below the patients in all categories above. If no questionnaire was available at baseline, change from baseline was not imputed.

End point type	Secondary
----------------	-----------

### End point timeframe:

At baseline and at week 12

End point values	Placebo	10 mg Empagliflozin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	156 <sup>[3]</sup>	156 <sup>[4]</sup>		
Units: Score on a scale				
median (inter-quartile range (Q1-Q3))	3.65 (-6.25 to 13.54)	7.29 (-2.60 to 18.75)		

### Notes:

[3] - Randomised Set (RS)

[4] - Randomised Set (RS)

## Statistical analyses

<b>Statistical analysis title</b>	Superiority of Empagliflozin vs. Placebo
-----------------------------------	--

### Statistical analysis description:

H0: There is no difference between the effect of placebo and the effect of empagliflozin.

Comparison groups	Placebo v 10 mg Empagliflozin
-------------------	-------------------------------

Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0893
Method	Wilcoxon rank test, normal approximation
Parameter estimate	Median difference (HL-estimate)
Point estimate	3.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	7.29

### Secondary: Change from baseline to week 12 in Chronic Heart Failure Questionnaire Self- Administered Standardized format (CHQ-SAS) dyspnea score

End point title	Change from baseline to week 12 in Chronic Heart Failure Questionnaire Self- Administered Standardized format (CHQ-SAS) dyspnea score
-----------------	---

End point description:

Change from baseline in CHQ-SAS was defined as the endpoint value at week 12 minus the last available endpoint value before start of treatment with randomised study medication. The CHQ-SAS evaluates 3 domains: dyspnoea, fatigue, and emotional function. Scores of the domains range from 1 to 7, with higher score indicating better quality of life. If no questionnaire was available at week 12, an imputed value was used. Patients with missing week 12 data who had no clinical event were ranked below any patient with non-missing data, but above the patients who had clinical events. Patients who died before week 12 were ranked below the patients in all categories above. If no questionnaire was available at baseline, change from baseline was not imputed. Subjects in the randomised set (RS) who have no missing values at baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

At baseline and at week 12

End point values	Placebo	10 mg Empagliflozin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	156 <sup>[5]</sup>	154 <sup>[6]</sup>		
Units: Score on scale				
median (confidence interval 95%)	0.40 (-0.33 to 0.83)	0.40 (-0.50 to 1.33)		

Notes:

[5] - Subjects in the randomised set (RS) who have no missing values at baseline.

[6] - Subjects in the randomised set (RS) who have no missing values at baseline.

### Statistical analyses

Statistical analysis title	Superiority of Empagliflozin vs. Placebo
----------------------------	--

Statistical analysis description:

H0: There is no difference between the effect of placebo and the effect of empagliflozin.

Comparison groups	Placebo v 10 mg Empagliflozin
-------------------	-------------------------------

Number of subjects included in analysis	310
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.4702
Method	Wilcoxon rank test, normal approximation
Parameter estimate	Median Difference (HL-estimate)
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.4

### Secondary: Change from baseline to week 6 in exercise capacity as measured by the 6-Minutes-Walking-Test (6MWT) distance

End point title	Change from baseline to week 6 in exercise capacity as measured by the 6-Minutes-Walking-Test (6MWT) distance
End point description:	
Change from baseline to week 6 in exercise capacity as measured by the distance walked in 6 minutes in standardised conditions. Change from baseline was defined as the distance walked in 6 minutes at week 6 minus the baseline value. Baseline value was defined as the last available measurement before start of treatment with randomised study medication.	
If a subject was present at the visit at week 6 but did not perform the 6MWT, the subject was evaluated as having walked a distance of 0 meter. If no value was available for week 6, an imputed value was used. Randomised Set (RS): All subjects that were randomised, regardless of whether treated or not.	
End point type	Secondary
End point timeframe:	
At baseline and at week 6	

End point values	Placebo	10 mg Empagliflozin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	156 <sup>[7]</sup>	156 <sup>[8]</sup>		
Units: Meter (m)				
median (inter-quartile range (Q1-Q3))	7.0 (-10.5 to 39.5)	9.5 (-12.5 to 32.0)		

Notes:

[7] - RS

[8] - RS

### Statistical analyses

Statistical analysis title	Superiority of Empagliflozin vs. Placebo
Statistical analysis description:	
H0: There is no difference between the effect of placebo and the effect of empagliflozin.	
Comparison groups	Placebo v 10 mg Empagliflozin

Number of subjects included in analysis	312
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.983
Method	Wilcoxon rank test, normal approximation
Parameter estimate	Median difference (HL-estimate)
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9
upper limit	9

## Secondary: Change from baseline to week 12 in Clinical Congestion Score

End point title	Change from baseline to week 12 in Clinical Congestion Score
End point description:	Change from baseline to week 12 in Clinical Congestion score is defined as the score-value at week 12 minus the score-value at baseline. Baseline value was defined as the last available measurement before start of treatment with randomised study medication. The Clinical Congestion score assessed the subjects congestion using a clinician-based outcome assessment of 6 different signs and symptoms: dyspnoea, orthopnoea, fatigue, jugular venous distention (as assessed by the investigator), rales, and oedema. Each category was assessed through a 4-measure questionnaire, which was further converted to a standardised 4-point scale ranging from 0 to 3, which 0 indicating no or fewer symptoms and 3 indicating continuous or more symptoms. Mean is adjusted mean. Only subjects in the randomised set (RS) who have baseline and at least one post-baseline value, are included in the analysis.
End point type	Secondary
End point timeframe:	At baseline and at week 12

End point values	Placebo	10 mg Empagliflozin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	153 <sup>[9]</sup>	155 <sup>[10]</sup>		
Units: Score on a scale				
arithmetic mean (standard error)	-0.30 (± 0.08)	-0.61 (± 0.08)		

Notes:

[9] - Only subjects in the randomised set (RS) who have baseline and at least one post-baseline value.

[10] - Only subjects in the randomised set (RS) who have baseline and at least one post-baseline value.

## Statistical analyses

Statistical analysis title	Effect of Empagliflozin vs Placebo
Statistical analysis description:	Mixed model repeated measure included treatment-by-visit interaction and baseline value-by-visit interaction as fixed effects. Unstructured covariance structure was used to model within-patient errors.
Comparison groups	Placebo v 10 mg Empagliflozin

Number of subjects included in analysis	308
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0053
Method	Mixed Model repeated Measures (MMRM)
Parameter estimate	Adjusted mean
Point estimate	-0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.53
upper limit	-0.09

### Secondary: Change from baseline to week 12 in Patient Global Impression of Severity (PGI-S) of Heart Failure Symptoms

End point title	Change from baseline to week 12 in Patient Global Impression of Severity (PGI-S) of Heart Failure Symptoms
-----------------	--

End point description:

Change from baseline to week 12 in PGI-S of Heart Failure Symptoms. The Patient Global Impression of Severity (PGI-S) of Heart Failure Symptoms is a 1-item questionnaire to assess the patient's impression of symptoms severity, specifically: shortness of breath, fatigue and swelling. The PGI-S asks the Patient to choose one response that best describes how his/her heart failure symptoms, specifically: shortness of breath, fatigue and swelling are now on a 5-point scale, ranging from 'Not at all' (1) to 'Very severe' (5). Number of participants by change in score are reported. Change in score was defined as the number of categories improved/deteriorated from baseline to week 12. Only subjects in the randomised set (RS) who have values at baseline and at week 12 are included in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At baseline and at week 12

End point values	Placebo	10 mg Empagliflozin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	149 <sup>[11]</sup>	147 <sup>[12]</sup>		
Units: Subjects				
4 categories improvement	0	0		
3 categories improvement	1	1		
2 categories improvement	13	14		
1 category improvement	41	41		
No change	73	74		
1 category deterioration	16	16		
2 categories deterioration	4	1		
3 categories deterioration	1	0		
4 categories deterioration	0	0		

Notes:

[11] - Only subjects in the randomised set (RS) who have values at baseline and at week 12.

[12] - Only subjects in the randomised set (RS) who have values at baseline and at week 12.

### Statistical analyses

<b>Statistical analysis title</b>	Effect of Empagliflozin vs Placebo
Statistical analysis description: Test on difference in mean treatment scores, based on modified ridit scores.	
Comparison groups	Placebo v 10 mg Empagliflozin
Number of subjects included in analysis	296
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.6189
Method	Cochran-Mantel-Haenszel test

## Secondary: Change from baseline to week 12 in Patient Global Impression of Severity (PGI-S) of dyspnoea

End point title	Change from baseline to week 12 in Patient Global Impression of Severity (PGI-S) of dyspnoea
End point description: Change from baseline to week 12 in Patient Global Impression of Severity (PGI-S) of dyspnoea. The PGI-S of Dyspnoea is a 1-item questionnaire designed to assess the participant's impression of symptom severity, specifically dyspnoea. The PGI-S item asks the participant to choose one response that best describes how his/her dyspnoea is now on a 5-point scale, ranging from 'Not at all' (1) to 'Very severe' (5). Number of subjects by change in score are reported. Change in score was defined as the number of categories improved/deteriorated from baseline to week 12. Only subjects in the randomised set (RS) who have values at baseline and at week 12 are included in the analysis.	
End point type	Secondary
End point timeframe: At baseline and at week 12	

End point values	Placebo	10 mg Empagliflozin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	147 <sup>[13]</sup>	150 <sup>[14]</sup>		
Units: Subjects				
4 categories improvement	0	0		
3 categories improvement	3	2		
2 categories improvement	8	11		
1 category improvement	38	46		
No change	83	70		
1 category deterioration	13	17		
2 categories deterioration	2	4		
3 categories deterioration	0	0		
4 categories deterioration	0	0		

Notes:

[13] - Only subjects in the randomised set (RS) who have values at baseline and at week 12.

[14] - Only subjects in the randomised set (RS) who have values at baseline and at week 12.

## Statistical analyses

<b>Statistical analysis title</b>	Effect of Empagliflozin vs Placebo
Statistical analysis description: Test on difference in mean treatment scores, based on modified ridit scores.	

Comparison groups	10 mg Empagliflozin v Placebo
Number of subjects included in analysis	297
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.6672
Method	Cochran-Mantel-Haenszel test

## Secondary: Patient Global Impression of Change (PGI-C) in Heart Failure Symptoms at week 12

End point title	Patient Global Impression of Change (PGI-C) in Heart Failure Symptoms at week 12
-----------------	--

End point description:

The Patient Global Impression of Change (PGI-C) in Heart Failure Symptoms is a 1-item questionnaire to assess the patient's impression of change in heart failure symptoms, specifically: shortness of breath, fatigue, and swelling. The PGI-C asks the patient to choose one Response that best describes the overall change (if any) in his/her heart failure symptoms, specifically: shortness of breath, fatigue, and swelling since he/she started taking the study medication on a 7- category scale ranging from 'Very much better' (+3) to 'Very much worse' (-3). Only subjects in the randomised set (RS) who have week 12 value are included in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At week 12

End point values	Placebo	10 mg Empagliflozin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	150 <sup>[15]</sup>	147 <sup>[16]</sup>		
Units: Subjects				
Very much worse	0	0		
Much worse	3	0		
A little worse	7	5		
No change	57	51		
A little better	40	52		
Much better	34	33		
Very much better	9	6		

Notes:

[15] - Only subjects in the randomised set (RS) who have week 12 value.

[16] - Only subjects in the randomised set (RS) who have week 12 value.

## Statistical analyses

Statistical analysis title	Effect of Empagliflozin vs Placebo
Statistical analysis description:	
Test on difference in mean treatment scores, based on modified ridit scores.	
Comparison groups	Placebo v 10 mg Empagliflozin

Number of subjects included in analysis	297
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.5147
Method	Cochran-Mantel-Haenszel test

## Secondary: Patient Global Impression of Change (PGI-C) in dyspnea at week 12

End point title	Patient Global Impression of Change (PGI-C) in dyspnea at week 12
End point description: The PGI-C in Dyspnoea is a 1-item questionnaire designed to assess the patient's Impression of change in dyspnoea. The PGI-C asks the patient to choose one response that best describes the change (if any) in his/her shortness of breath when performing usual activities since he/she started taking the study medication on a 7-category scale ranging from 'Very much better' (+3) to 'Very much worse' (-3). Only subjects in the randomised set (RS) who have week 12 value are included in the analysis.	
End point type	Secondary
End point timeframe: At week 12	

End point values	Placebo	10 mg Empagliflozin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	149 <sup>[17]</sup>	147 <sup>[18]</sup>		
Units: Subjects				
Very much worse	0	0		
Much worse	2	0		
A little worse	6	3		
No change	52	49		
A little better	45	59		
Much better	34	30		
Very much better	10	6		

Notes:

[17] - Only subjects in the randomised set (RS) who have week 12 value.

[18] - Only subjects in the randomised set (RS) who have week 12 value.

## Statistical analyses

Statistical analysis title	Effect of Empagliflozin vs Placebo
Statistical analysis description: Test on difference in mean treatment scores, based on modified ridit scores.	
Comparison groups	Placebo v 10 mg Empagliflozin
Number of subjects included in analysis	296
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.863
Method	Cochran-Mantel-Haenszel test



---

**Secondary: Relative change from baseline to week 12 in N-terminal pro-brain natriuretic peptide (NTproBNP)**

---

End point title	Relative change from baseline to week 12 in N-terminal pro-brain natriuretic peptide (NTproBNP)
-----------------	---

End point description:

Relative change from baseline to week 12 in N-terminal pro-brain natriuretic peptide (NTproBNP). Baseline value was defined as the mean of all available measurements from the screening visit until start of treatment with randomised study medication. Only subjects in the randomised set (RS), who had values at baseline and at least one post baseline value are included in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 3 weeks prior to treatment start and at Week 12

---

End point values	Placebo	10 mg Empagliflozin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	153 <sup>[19]</sup>	155 <sup>[20]</sup>		
Units: Ratio of adjusted geometric means				
number (confidence interval 95%)	0.98 (0.90 to 1.06)	0.89 (0.82 to 0.97)		

Notes:

[19] - Subjects in the randomised set, who have values at baseline and at least on post baseline value.

[20] - Subjects in the randomised set, who have values at baseline and at least one post-baseline value.

**Statistical analyses**

Statistical analysis title	Effect of Empagliflozin vs Placebo
----------------------------	------------------------------------

Statistical analysis description:

The endpoint 'relative change from baseline in NT-proBNP at Week 12' (after log-transformation) was evaluated using an MMRM analysis over time with baseline log-transformed NT-proBNP-by-visit interaction and visit-by-treatment interaction as covariates. Unstructured covariance structure was used to model within-patient errors.

Comparison groups	Placebo v 10 mg Empagliflozin
Number of subjects included in analysis	308
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.141
Method	Mixed Model repeated Measures (MMRM)
Parameter estimate	Adjusted geometric mean ratio
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	1.03



## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

From first intake of study medication, until 7 days after last intake of study medication, up to 91 days.

Adverse event reporting additional description:

Treated Set: All participants who were treated with at least 1 dose of the study medication.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

### Reporting groups

Reporting group title	10 mg Empagliflozin
-----------------------	---------------------

Reporting group description:

1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily for 12 weeks in subjects with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction (LVEF $\leq$ 40%).

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

1 film-coated tablet of placebo matching empagliflozin was administered orally once daily for 12 weeks in subjects with chronic Heart Failure (CHF) with reduced left ventricular ejection fraction (LVEF $\leq$ 40%).

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No non-serious adverse events were reported for both arms.

Serious adverse events	10 mg Empagliflozin	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	21 / 155 (13.55%)	27 / 156 (17.31%)	
number of deaths (all causes)	3	3	
number of deaths resulting from adverse events	3	3	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung cancer metastatic			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypertensive urgency			

subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	2 / 155 (1.29%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Oedema peripheral			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atelectasis			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pulmonary oedema			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device malfunction			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 155 (0.65%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			

subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	6 / 155 (3.87%)	12 / 156 (7.69%)	
occurrences causally related to treatment / all	0 / 6	1 / 12	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac failure acute			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congestive cardiomyopathy			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	2 / 155 (1.29%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dizziness			

subjects affected / exposed	1 / 155 (0.65%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somnolence			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Duodenal ulcer haemorrhage			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Gastrointestinal haemorrhage subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mallory-Weiss syndrome subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders Cholelithiasis subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver injury subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders Subcutaneous emphysema subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders Acute kidney injury subjects affected / exposed	1 / 155 (0.65%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cyst			



subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Renal injury			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Musculoskeletal and connective tissue disorders			
Spinal pain			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Parotitis			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	2 / 155 (1.29%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval abscess			
subjects affected / exposed	0 / 155 (0.00%)	1 / 156 (0.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	1 / 155 (0.65%)	0 / 156 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	10 mg Empagliflozin	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 155 (0.00%)	0 / 156 (0.00%)	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 May 2018	<p>The following changes were introduced by the first global protocol amendment:</p> <ul style="list-style-type: none"><li>• Clarification of the inclusion criteria regarding medical therapy for heart failure (HF) (it was allowed to include patients who were not treated according to local guidelines, in such cases the investigator had to document the reasons)</li><li>• Clarification of the exclusion criteria regarding exclusion of patients randomised in another empagliflozin HF trial (a patient could be a screen failure in another trial and then be considered for inclusion into this trial)</li></ul> <p>• Flowchart: Recommendation that NT-proBNP and safety laboratory measures should be done first at the Screening Visit and then other procedures could be done on a later day</p> <ul style="list-style-type: none"><li>• Updates to reflect the final version of the CHQ-SAS questionnaire</li><li>• Clarification that re-testing for eligibility criteria could be done only once</li><li>• Clarification that screening data of patients who failed screening can be used in the parallel trial 1245-0167</li><li>• Clarification of the exclusion criteria regarding major surgery (patients were not eligible for the trial if they had major surgery scheduled during the duration of the trial)</li><li>• Update of requirements for emergency situations</li><li>• Change of instructions for physical examinations</li><li>• Editorial changes and clarifications regarding the conduct of the 6MWT (described in detail in the Appendix of the CTP)</li></ul>
20 July 2018	<p>The following changes were introduced by the second global protocol amendment:</p> <ul style="list-style-type: none"><li>• Change of the inclusion criteria regarding the NT-proBNP level at baseline (influence of atrial fibrillation was taken into account, new levels were &gt;450 pg/ml for patients without atrial fibrillation and &gt;600 pg/ml for patients with atrial fibrillation)</li><li>• Flow chart: Clarification that at the time of the NT-proBNP measurement, the baseline rhythm of the patient (e.g. sinus rhythm, atrial fibrillation) had to be determined (i.e. by ECG) in order to assess eligibility (see NT-proBNP cut-offs above)</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported